GlaxoSmithKline's Pioneering Bird Flu Vaccine Gets FFA Sciences Approval

The U.S. Food and Drug Administration or FDA, Friday said it approved GlaxoSmithKline Plc's (GSK: Quote,GSK.L), first adjuvanted Influenza A (H5N1) Virus Monovalent Vaccine, for the prevention of H5N1 influenza. The vaccine is not intended for commercial use, and has been purchased by the U.S. Department of Health and Human Services from its maker, ID Biomedical Corporation of Quebec, an unit of GlaxoSmithKline Biologicals. This purchase would add the vaccine within the National Stockpile for distribution by public health officials if needed.

Help employers find you! Check out all the jobs and post your resume.